Ghady Haidar1, Nina Singh. 1. aDivision of Infectious Diseases, University of Pittsburgh Medical Center bVA Pittsburgh Healthcare System, Infectious Diseases Section, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Abstract
PURPOSE OF REVIEW: To summarize new discoveries in viral pathogenesis and novel therapeutic and prophylactic strategies in organ transplant recipients. RECENT FINDINGS: For decades, prophylaxis of cytomegalovirus (CMV) has been the standard preventive strategy, but new clinical trials are expected to determine the advantages of preemptive therapy over prophylaxis. Novel anti-CMV agents, such as maribavir and letermovir, are being studied for the treatment of resistant/refractory CMV as alternatives to foscarnet and cidofovir. CMV immune monitoring may offer individualized management plans. Epstein-Barr virus infections in transplant recipients are difficult to prevent and treat, though recent data suggest possible merit to pretransplant rituximab among high-risk transplant recipients. We review the groundbreaking HIV-to-HIV organ transplant trials, which are expected to revolutionize the care of HIV-infected individuals. Finally, we review topical developments in human herpesvirus 8, Zika virus, RNA respiratory viruses, adenovirus, norovirus, and polyoma viruses in organ transplantation. SUMMARY: Ongoing trials to optimize CMV prophylaxis and treatment, and outcomes of HIV-to-HIV organ transplantation in the United States, have significant implications to optimize management of these viruses in transplant recipients. Assessment of new antivirals and antiviral strategies, such as adoptive immunotherapy, is warranted for refractory viral infections.
PURPOSE OF REVIEW: To summarize new discoveries in viral pathogenesis and novel therapeutic and prophylactic strategies in organ transplant recipients. RECENT FINDINGS: For decades, prophylaxis of cytomegalovirus (CMV) has been the standard preventive strategy, but new clinical trials are expected to determine the advantages of preemptive therapy over prophylaxis. Novel anti-CMV agents, such as maribavir and letermovir, are being studied for the treatment of resistant/refractory CMV as alternatives to foscarnet and cidofovir. CMV immune monitoring may offer individualized management plans. Epstein-Barr virus infections in transplant recipients are difficult to prevent and treat, though recent data suggest possible merit to pretransplant rituximab among high-risk transplant recipients. We review the groundbreaking HIV-to-HIV organ transplant trials, which are expected to revolutionize the care of HIV-infected individuals. Finally, we review topical developments in human herpesvirus 8, Zika virus, RNA respiratory viruses, adenovirus, norovirus, and polyoma viruses in organ transplantation. SUMMARY: Ongoing trials to optimize CMV prophylaxis and treatment, and outcomes of HIV-to-HIV organ transplantation in the United States, have significant implications to optimize management of these viruses in transplant recipients. Assessment of new antivirals and antiviral strategies, such as adoptive immunotherapy, is warranted for refractory viral infections.
Authors: Zheng Zhang; Longhui Qiu; Shixian Yan; Jiao-Jing Wang; Paul M Thomas; Manoj Kandpal; Lihui Zhao; Andre Iovane; Xue-Feng Liu; Edward B Thorp; Qing Chen; Mary Hummel; Yashpal S Kanwar; Michael M Abecassis Journal: Am J Transplant Date: 2019-05-14 Impact factor: 8.086
Authors: Se Hyun Choi; Chang Ho Yoon; Hyun Ju Lee; Hong Pyo Kim; Jong Min Kim; Jeong-Hwan Che; Kyoung Min Roh; Hyuk Jin Choi; Jiyeon Kim; Eung Soo Hwang; Chung-Gyu Park; Mee Kum Kim Journal: Xenotransplantation Date: 2018-07 Impact factor: 3.907
Authors: Sahra Pajenda; Sebastian Kapps; Daniela Gerges; Gregor Hoermann; Ludwig Wagner; Nina Buchtele; Barbara Geist; Robert Strassl; Alice Schmidt; Wolfgang Winnicki Journal: BMC Nephrol Date: 2021-05-08 Impact factor: 2.388
Authors: Nina Singh; Drew J Winston; Raymund R Razonable; G Marshall Lyon; Fernanda P Silveira; Marilyn M Wagener; Ajit P Limaye Journal: J Infect Dis Date: 2021-03-29 Impact factor: 5.226